Regeneron Pharmaceuticals (REGN) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 52.2% versus a gain of 21.8%. Over five years, TAK leads with a +60.9% price change compared with +43.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($95.24 billion vs $69.55 billion), about 1.4 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.8x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 0.40%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | TAK |
|---|---|---|
| Share price | $920.69 | $21.77 |
| Market cap | $95.24B | $69.55B |
| 1-day change | -0.19% | +1.68% |
| YTD return | +19.28% | +39.64% |
| 1-year return | +21.80% | +52.24% |
| 5-year return | +43.11% | +60.90% |
| P/E ratio (TTM) | 20.35 | 311.00 |
| Forward P/E | 12.85 | 41.08 |
| EPS (TTM) | $45.24 | $0.07 |
| Dividend yield | 0.40% | 927.88% |
| Annual dividend | $3.70 | $202.00 |
| Revenue (latest FY) | $14.34B | — |
| Revenue growth (YoY) | +0.99% | — |
| Net income (latest FY) | $4.50B | — |
| Operating margin | 24.95% | — |
| Net margin | 31.41% | — |
| 52-week high | $991.73 | $22.07 |
| 52-week low | $591.52 | $14.16 |
| Distance from 52-week high | -7.16% | -1.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +7.64% | +12.68% |
| Average volume | 805.45K | 2.73M |
| Shares outstanding | 101.63M | 3.19B |
| Employees | 15,410 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed REGN by 30.4 percentage points over the past year.
- Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 20.4x trailing P/E).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.40%).
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
REGN vs TAK FAQ
Which is bigger, Regeneron Pharmaceuticals or Takeda Pharmaceutical?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $95.24B compared with $69.55B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, REGN or TAK?
TAK returned +52.24% over the past 12 months, compared with +21.80% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or TAK?
REGN has the lower trailing P/E at 20.4, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 927.88%, compared with 0.40% for Regeneron Pharmaceuticals.
Are Regeneron Pharmaceuticals and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.